Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Alimta | Pemetrexed | Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Avastin (with capecitabine) | Bevacizumab | Metastatic Colorectal Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Avastin | Bevacizumab | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Bosulif | Bosutinib | Chronic Myeloid Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erivedge | Vismodegib | Basal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Halaven | Eribulin Mesylate | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Istodax | Romidepsin | Peripheral T-Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jakavi | Ruxolitinib | Myelofibrosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kadcyla | Trastuzumab emtansine | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Mekinist | Trametinib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 20, 2024